Palliative therapy in patients suffering from carcinomas of the biliary tract;Palliative therapie der karzinome des biliaren systems

Medizinische Klinik

Volumn 92, Issue 7, 1997, Pages 401-405

  Lersch, Christian ^a   Classen, Meinhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Carcinoma of the gallbladder; Cholangiocarcinoma; Palliation

Indexed keywords

ALPHA2B INTERFERON; AMSACRINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DIPYRIDAMOLE; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; METHOTREXATE; MITOMYCIN; PACLITAXEL; SEMUSTINE; STREPTOZOCIN; TAMOXIFEN; TEGAFUR;

ADULT; AGED; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; ENDOSCOPIC SURGERY; GALLBLADDER CARCINOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OBSTRUCTIVE JAUNDICE; QUALITY OF LIFE; REVIEW; STENT; SURVIVAL TIME; TUMOR REGRESSION;

EID: 0030738428     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03042570     Document Type: Review

References (52)

1. Ajiki, T., H. Onoyama, M. Yamamoto, T. Fujimori, S. Maeda, Y. Saitoh: Detection of point mutations in k-ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures, Int. J. Pancreat. 18 (1995), 215-220.
2. Ajiki, T., T. Fujimori, H. Onoyama, M. Yamamoto, S. Kitazawa, S. Maeda, Y. Saitoh: K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 38 (1996), 426-429.
3. Altaee, M. Y., P. J. Johnson, J. M. Farrant, R. Williams: Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 68 (1991), 2051-2055.
4. Banerjee, B., S. K. Teplick: Nonsurgical management of primary cholangiocarcinoma. Retrospective analysis of 40 cases. Dig. Dis. Sci. 40 (1995), 701-705.
5. Bukowski, R. M., L. P. Leichman, S. E. Rivkin: Phase II trial of m-ASMA in gallbladder and cholangiocarcinoma: A Southwest Oncology Group study. Europ. J. Cancer clin. Oncol. 6 (1983), 721-723.
6. Colleoni, M., M. DiBartolomeo, A. DiLeo, N. Zilembo, C. Carnaghi, A. Pandolfi, L. Rimassa, S. Artale, E. Bajetta: Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Europ. J. Cancer 31A (1995), 2426-2427.
7. Crooke, S. T., W. T. Bradner: Mitomycin-C: A review. Cancer Treatm. Rev. 3 (1976), 121-139.
8. Ellis, P. A., A. Norman, A. Hill, M. E. R. O'Brían, M. Nicolson, T. Hickish, D. Cunningham. Epirubicin, cisplatin and infusional 5-fluorouracil (5-Fu) (ECF) in hepatobiliary tumours. Europ. J. Cancer 31A (1995), 1594-1598.
9. Falkson, G., J. M. MacIntyre, C. G. Moertel: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54 (1984), 965-969.
10. Flickinger, J. C., A. H Epstein, S. Iwatsuki, B. I. Carr, T. E Starzl: Radiation therapy for primary carcinoma of the extrahepatic biliary system. Cancer 68 (1991), 289-294.
11. Garnick, M. B., W. D. Ensminger, M. Israel: A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res. 39 (1979), 4105-4110.
12. Gebbia, V., E. Majello, A. Testa, G. Pezzella, S. Giuseppe, F. Giotta, F. Riccardi, S. Fortunato, G. Colucci, N. Gebbia, Southern Italy Oncology Group: Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Cancer 78 (1996), 1300-1307.
13. Goldstein, R. M., M. Stone, G. W. Tillery, N. Senzer, M. Levy, B. S. Husberg, T. Gonwa, G. Klintmahn: Is liver transplantation indicated for cholangiocarcinoma? Amer. J. Surg. 166 (1993), 768-771.
14. Grove, M. K., R. E. Hermann, D. P. Vogt, T. A. Broughan: Role of radiation after operative palliation in cancer of the proximal bile ducts. Amer. J. Surg. 161 (1991), 454-458.
15. Hall, S. H., R. S. Benjamin, W. K. Murphy et al.: Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 44 (1974), 2008-2013.
16. Hanada, K., M. Itoh, K. Fujii, A. Tsuchida, H. Ooishi, G. Kajiyama: K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct Cancer 77 (1996), 452-458.
17. Harvey, J. H., F. P. Smith, P. S. Schein: 5-flaorouracil, mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract. J. clin. Oncol. 2 (1984), 1245-1248.
18. Haskell, C. M.: Cancer of the liver. In: Haskell, C. M. (ed.): Cancer treatment. Saunders, Philadelphia 1980, p. 319-357.
19. Hayashi, S., M. Miyazaki, Y. Kondo, N. Nakajima: Invasive growth patterns of hepatic hilar ductal carcinoma. Cancer 73 (1994), 2922-2929.
20. Isacoff, W. H., L. Botnick, R. Tompkins, A. D. Jacobs, H. Reber, O. Taylor: Treatment of patients with advanced tumors of the bile ducts with continuous infusion (CI) 5-fluorouracil (5-FU) in conjunction with calcium leucovorin (LV), mitomycin-C (Mito-C), and dipyridamole (D). Proc. Amer. Soc. clin. Oncol. 12 (1993), 225.
21. Jan, Y. Y., L. B. Jeng, T. L. Hwang, C. S. Wang, M. F. Chen, T.J. Chen: Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepato-Gastroent. 43 (1996), 614-619.
22. Jones, D. V., R, Lozano, A. Hoque, A. Markowitz, Y. Z. Patt. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J. clin. Oncol. 14 (1996), 2306-2310.
23. Kajanti, M., S. Pyrhönen: Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Amer. J. clin. Oncol. 17 (1994), 223-226.
24. Koda, K., O. Nakazawa, K. Morita et al.: Combination chemotherapy of UFT with adriamycin (ADM) and cisplatin (CDDP) for advanced gastrointestinal cancer. Gan To Kagaku Ryoho 17 (1990), 1893-1900.
25. Lee, J. G., J. W. Ieung, J. Baillie, L. J. Layfield, P. B. Cotton: Benign, dysplastic, or malignant - making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Amer. J. Gastroent. 90, 5 (1995), 722-726.
26. Massey, W. H., W. S. Fletcher, M. P. Judkins, D. L. Dennis; Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters. Amer. J. Surg. 121 (1971), 160-164.
27. Mathieson, J. R , R. F. McLoughlin, P. L. Cooperberg, C C. Prystai, S N. Stordy, J. K. MacFarlane, N. Schmidt: Malignant obstruction of the common bile duct: long-term results of Gianturco-Rosch metal stents used as initial treatment. Radiology 192 (1994), 663-667.
28. Moerman, C. J., M. P. H. Berns, H. B. Bueno de Mesquita, S. Runa: Reproductive history and cancer of the biliary trace in women. Int. J. Cancer 57 (1994), 146-153.
29. Monson, J. R., J. H. Donohue, L. L. Gunderson, D. M. Nagorney, C. E. Bender, H. S. Wieand. Intraoperative radiotherapy for unresectable cholangiocarcinoma - the Mayo Clinic experience. Surg. Oncol. 1 (1992), 283-290.
30. Nagorney, D. M., G. A. D. McPhersoǹ: Carcinoma of the gallbladder and extrahepatic bile ducts. Semin. Oncol. 15 (1988), 106-115.
31. Nevin, J. E., T. J. Moran, S. Kay, R. King: Carcinoma of the gallbladder: Staging, treatment and prognosis. Cancer 37 (1976), 141-148.
32. Ohashi, K., M. Tsutsumi, Y., Nakajiama, Y., H. Nakano, Y. Konishi; Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Brit. J. Cancer 74 (1996), 930-935.
33. Ohashi, K., Y. Nakajiama, H. Kanehiro, M. Tsutsumi, J Taki, Y. Aomatsu, A. Yoshimura, S. Ko, T. Kin, K. Yagura, Y. Konishi, H. Nakano: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology Gastroenterology 109 (1995), 1612-1617.
34. Ohnishi, H., M. Asada, Y. Shichijo, N. Iijima, E. Itobayashi, K. Shimura, T. Suzuki, S Yoshida, T. Mine: External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepato-Gastroent. 42 (1995), 265-268.
35. Okada, S., H. Ishii, H. Nose, M. Yoshimori, T. Okusaka, K. Aoki, M. Iwasaki, J. Furuse, M. Yoshino: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51 (1994), 515-557.
36. O'Brien, S., A. R. W. Hatfield, P. I. Craig, S. P. Williams: A three year follow up of self expanding metal stents in the endoscopic palliation of longterm survivors with malignant biliary obstruction. Gut 36 (1995), 618-621.
37. Patt, Y. Z , D. V. Jones, A. Hoque, R Lozano, A. Markowitz, I. Raijman, P. Lynch, C Charnsangavej. Phase II trial of intravenous fluorouracil and subcutaneous interferon alpha-2b for biliary tract cancer J. clin. Oncol. 14 (1996), 2311-2315.
38. Pichlmayr, R., P. Lamesch, A. Weimann, G. Tusch, B. Ringe: Surgical treatment of cholangiocellular carcinoma Wld J. Surg. 19 (1995), 83-88.
39. Ponchon, T., P. Gagnon, F. Berger, M. Labadie, A. Liaras, A. Chavaillon, R. Bory: Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest. Endosc. 42 (1995), 565-572
40. Pradeep, R., S. P. Kaushik, S. S Sikora, B. N. Bhattacharya, C. M. Pandey, V. K. Kapoor. Predictors of survival in patients with carcinoma of the gallbladder. Cancer 76 (1995), 1145-1149.
41. Rizzi, P. M., S. D. Ryder, B. Portmann, J. K Ramage, N. V. Naoumov, R. Williams: p53 protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 38 (1996), 265-268.
42. Rougier, P., A. Fandi, M. Dureux, L. Fandi, M. C. Fabri, J. Zarba, J. Kac, J. P. Armand: Demonstrated efficiency of 5-fluorouracil (5-Fu) continuous infusion (CI) and cisplatin (P) in patients with advanced biliary tract carcinoma. Proc. Amer. Soc. clin. Oncol. 14 (1995), 205.
43. Sanz-Altamira, P. M . M. S. Huberman, K. Ferrante, K. E. Stuart: Phase II study of 5-Fu, leucovorin, and carboplatin in unresectable cholangiocarcinoma. Proc. Amer. Soc. clin. Oncol. 15 (1996), 219.
44. Shibata, T., T. Sato, H. Konda, I. Ootani et al.: Two cases of obstructive jaundice due to extrahepatic carcinoma of the bile duct with marked response to daily oral administration of etoposide. Gan To Kagaku Ryoho 17 (1990), 2429-2432.
45. Shirai, Y., K. Tsukada, T. Ohtani, H. Watanabe, K. Hatakeyama: Hepatic metastases from carcinoma of the gallbladder. Cancer 75 (1995), 2063-2068.
46. Tamada, K., K. Ido, N. Ueno, M. Ichiyama, T. Tomiyama, T. Nishizono, S. Wada, T. Noda, S. Tano, T. Aizawa, T. Ueno, K. Kimura: Assessment of hepatic artery invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 27 (1995), 579-583.
47. Tamada, K., K. Ido, N. Ueno, M. Ichiyama, T. Tomiyama, T. Nishizono, S Wada, T. Noda, S. Tano, T. Aizawa, T. Ueno, K. Kimura: Assessment of portal vein invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 27 (1995), 573-578.
48. Tavey, M., M. Hester: Phase II study of adriamycin plus bleomycin for the treatment of hepatocellular and biliary tract carcinoma. Proc Amer. Soc. clin. Oncol. 20 (1979), 415.
49. Vaittínen, E.: Carcinoma of the gallbladder: A study of 390 cases diagnosed in Finland, 1953-1967. Ann. Chir. Gynaec. 59 (1970), 1-81.
50. Veeze-Kuijpers, B., J. H. Meerwaldt, J. S. Lameris, M. van Blankenstein, W. L. J. van Putten, O. T. Terpstra: The role of radiotherapy in the treatment of bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 18 (1990), 63-67.
51. Vij, J. C., A. Govil, A. Chaudhary, R. Gulati, S. Mehta, S. Ganguli: Endoscopic biliary endoprosthesis for palliation of gallbladder carcinoma. Gastrointest. Endosc. 43 (1996), 121-123.
52. Watkins, E., R. A. Oberfield, B. Cady, M. E. Clouse: Arterial infusion chemotherapy of diffuse hepatic malignancies. Progr. clin. Cancer 7 (1978), 235-245.